Topical minoxidil effective for treating hair loss after COVID-19 infection: Study

Japan: Topical minoxidil is an effective treatment option for better management of hair loss after SARS-CoV-2 infection (HLASCI) and can be used as an adjunct to optimal care of patients with COVID-19 disease, findings from a literature review revealed. 

"Although it is necessary to further study the pathophysiology underlying HLASCI, our study indicates that acute telogen effluvium (TE) is the main cause of HLASCI," Manabu Ohyama, Department of Dermatology, Kyorin University Faculty of Medicine, Tokyo, Japan, and colleagues wrote in their study published in the Journal of Dermatology. 

The WHO has declared coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to be a pandemic that continues to have a major impact on society. Several studies have reported impaired health sequelae after COVID-19 recovery, one of which is hair loss. People with hair loss experience a substantial mental burden, which potentially hampers their social life. However, few studies have systematically analyzed the details including hair loss.

Against the above background, the team conducted a narrative review using PubMed on the frequency, associated comorbidities, disease characteristics, and treatment of hair loss after SARS-CoV-2 infection. 28 articles were identified using two search strings. 

"Topical minoxidil has used widely for AGA patients, who have been speculated to exhibit poor resistance to SARS-CoV-2," wrote the authors. "Topical minoxidil may provide relief from HLASCI, but to confirm this observation, future clinical research is warranted."

Reference:

Ohyama M, Matsudo K, Fujita T. Management of hair loss after severe acute respiratory syndrome coronavirus 2 infection: Insight into the pathophysiology with implication for better management. J Dermatol. 2022 May 27. doi: 10.1111/1346-8138.16475. Epub ahead of print. PMID: 35633047.